Allogeneic hematopoietic stem cell transplantation (allo-HSCT) use in refractory/relapsed B-cell non-Hodgkin lymphoma (R/R B-NHL) has been reduced due to the efficacy of CAR-T-cell therapy as salvage treatment. However, there remains a need for data regarding the long-term outcomes following allo-HSCT, to fully characterize this procedure as a benchmark to design further studies on the role of allogeneic stem cell transplantation. The present study was lauched to assess the long-term outcomes of R/R B-NHL patients after allo-HSCT, in a multicenter study among six Italian hematology centers. Data were collected from 285 allo-HSCT procedures performed among 281 R/R B-NHL patients, in 2000 to 2020. All patients signed informed consent for sharing data with the GITMO/EBMT Registry, and the study was approved by the Institutional Review Board of the coordinating center. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), cumulative incidence function (CIF) of disease-related death, and non-relapse mortality (NRM). The median age at transplant was 50 yr (19 to 70), with 94 (33%) female patients. Histological subsets included indolent lymphoma (123 patients; 43.3%), aggressive lymphoma (124; 43.7%), and mantle-cell lymphoma (MCL; 37; 13%). At allo-HSCT, 135 patients (47.7%) exhibited complete remission (CR), 63 (22.3%) partial response, 30 (10.6%) stable disease, and 55 (19.4%) progressing disease. Myeloablative regimens were employed in 86 procedures (30.2%). The median follow-up for surviving patients was 8.7 yr (0.3 to 22). Three-year PFS was 43.7% (95% CI 37.9 to 49.4), 9-yr PFS 39.3% (33.4 to 45.1), 3-yr OS 50.4% (44.5 to 56.1), and 9-yr OS 46.6% (40.5 to 52.5). Positive predictors of 3-yr PFS included indolent lymphoma (55.3%) versus aggressive (37.9 %) and MCL (27.0%); and CR at allo-HSCT (51.9%) vs non-CR (30.9% to 38.9%). Similar associations were observed for OS
Sica, S., Long-Term Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: An Italian Multicenter Collaborative Study, <<TRANSPLANTATION AND CELLULAR THERAPY>>, 2025; (31): 806-806 [https://hdl.handle.net/10807/328800]
Long-Term Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: An Italian Multicenter Collaborative Study
Sica, Simona
Penultimo
Membro del Collaboration Group
2025
Abstract
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) use in refractory/relapsed B-cell non-Hodgkin lymphoma (R/R B-NHL) has been reduced due to the efficacy of CAR-T-cell therapy as salvage treatment. However, there remains a need for data regarding the long-term outcomes following allo-HSCT, to fully characterize this procedure as a benchmark to design further studies on the role of allogeneic stem cell transplantation. The present study was lauched to assess the long-term outcomes of R/R B-NHL patients after allo-HSCT, in a multicenter study among six Italian hematology centers. Data were collected from 285 allo-HSCT procedures performed among 281 R/R B-NHL patients, in 2000 to 2020. All patients signed informed consent for sharing data with the GITMO/EBMT Registry, and the study was approved by the Institutional Review Board of the coordinating center. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), cumulative incidence function (CIF) of disease-related death, and non-relapse mortality (NRM). The median age at transplant was 50 yr (19 to 70), with 94 (33%) female patients. Histological subsets included indolent lymphoma (123 patients; 43.3%), aggressive lymphoma (124; 43.7%), and mantle-cell lymphoma (MCL; 37; 13%). At allo-HSCT, 135 patients (47.7%) exhibited complete remission (CR), 63 (22.3%) partial response, 30 (10.6%) stable disease, and 55 (19.4%) progressing disease. Myeloablative regimens were employed in 86 procedures (30.2%). The median follow-up for surviving patients was 8.7 yr (0.3 to 22). Three-year PFS was 43.7% (95% CI 37.9 to 49.4), 9-yr PFS 39.3% (33.4 to 45.1), 3-yr OS 50.4% (44.5 to 56.1), and 9-yr OS 46.6% (40.5 to 52.5). Positive predictors of 3-yr PFS included indolent lymphoma (55.3%) versus aggressive (37.9 %) and MCL (27.0%); and CR at allo-HSCT (51.9%) vs non-CR (30.9% to 38.9%). Similar associations were observed for OS
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
